Cytomegalovirus Infections: all 362 studies

Page 4 of 4. Open to participants first (59), then studies with results posted, then the rest; newest registration first within each.

• Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) ChallengeCompletedNCT00373412Phase 1
• Prophylaxis With Ganciclovir Improves Graft Survival in Renal Allograft RecipientsCompletedNCT00373165Phase 4
• Phase 1 Trial of CMV Towne Vaccine in Subjects Previously Received VCL CT02 Vaccine ID or IMCompletedNCT00370006Phase 1
• CMV Infection in Adolescent MalesTerminatedNCT00302029
• CMV Glycoprotein B Vaccine in Allograft RecipientsStatus unknownNCT00299260Phase 2
• Artesunate in Preemptive Treatment of Human Cytomegalovirus (CMV) in Stem Cell Transplant RecipientsCompletedNCT00284687Phase 3
• A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.CompletedNCT00273143
• Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement TherapyTerminatedNCT00264368Phase 4
• Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell TransplantTerminatedNCT00241345Phase 3
• MICI-CMV:Valganciclovir in Recurrent Bouts of Cryptogenic Inflammatory Bowel Diseases With an Infection by CytomegalovirusTerminatedNCT00237653Phase 3
• Genotyping of Cytomegalovirus From Patients in IsraelStatus unknownNCT00228202
• Maribavir for Prevention of CMV After Stem Cell TransplantsCompletedNCT00223925Phase 2
• Cytomegalovirus (CMV) Infection in PregnancyCompletedNCT00194155
• Cytomegalovirus (CMV) Infection in Amniotic FluidCompletedNCT00194142
• Risk Factors for Cytomegalovirus Disease in Solid Organ TransplantationCompletedNCT00170170
• Evaluation of Interferon-gamma Responses to HCMV Infection in HIV Positive IndividualsCompletedNCT00168259
• gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent FemalesCompletedNCT00133497Phase 2
• Recombinant CMV gB Vaccine in Postpartum WomenCompletedNCT00125502Phase 2
• Cytotoxic T-Lymphocytes for the Prophylaxis of Cytomegalovirus After Allogeneic Stem Cell TransplantCompletedNCT00078533Phase 1
• Immune Response to CytomegalovirusCompletedNCT00034437
• Valganciclovir in Congenital CMV InfantsCompletedNCT00031434Phase 1/2
• Neonatal CMV-Ganciclovir Follow-up StudyCompletedNCT00031421
• Transfusion Infections Pediatric Prospective Study (TRIPPS)CompletedNCT00029406
• Clinical and Genetic Analysis of Enlarged Vestibular AqueductsCompletedNCT00023036
• Valganciclovir to Prevent Cytomegalovirus Infection in Patients Following Donor Stem Cell TransplantationCompletedNCT00016068Phase 3
• Cytomegalovirus Spread and Reactivation in Blood CellsCompletedNCT00006314
• Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIVCompletedNCT00006145Phase 3
• A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) InfectionCompletedNCT00005572
• Infection and Cardiovascular DiseaseCompletedNCT00005547
• Inflammation, Infection, and Future Cardiovascular RiskCompletedNCT00005496
• Prospective Study of HIV Infection in HemophiliacsCompletedNCT00005309
• Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2)CompletedNCT00005274
• Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System DiseaseCompletedNCT00004642Phase 1/2
• Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCRStatus unknownNCT00004573Not applicable
• Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus InfectionCompletedNCT00004278Phase 3
• The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected PatientsCompletedNCT00002373Phase 1
• A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the EyesCompletedNCT00002355Not applicable
• A Study of Lobucavir in Patients With AIDSCompletedNCT00002352Not applicable
• A Phase I Study of the Safety of Proleukin (Aldesleukin) in Combination With Ganciclovir and Antiretroviral Therapy in HIV Seropositive Patients With Cytomegalovirus (CMV) RetinitisCompletedNCT00002321Phase 1
• A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With GanciclovirStatus unknownNCT00002301Not applicable
• A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or ViruriaCompletedNCT00002268Phase 1
• A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral GanciclovirCompletedNCT00002251Not applicable
• Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot StudyCompletedNCT00002146Phase 4
• A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and DidanosineCompletedNCT00002096Phase 1
• A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency VirusCompletedNCT00002095Not applicable
• Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised PatientCompletedNCT00002025Not applicable
• Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus InfectionsCompletedNCT00002024Not applicable
• Comparison of Two Test Methods-NASBA and Antigenemia-for Detecting Cytomegalovirus InfectionCompletedNCT00001976
• Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic InfectionsCompletedNCT00001890Phase 2
• Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial DysfunctionCompletedNCT00001531
• A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.CompletedNCT00001100Phase 3
• A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected PatientsCompletedNCT00001089
• The Safety and Effectiveness of Adefovir Dipivoxil in the Treatment of HIV-Infected PatientsCompletedNCT00001082Phase 3
• A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected PatientsCompletedNCT00001038Phase 3
• The Safety and Effectiveness of Ganciclovir in the Prevention of Cytomegalovirus (CMV) of the Eyes and Disease of the Stomach and Intestines in Patients With HIVCompletedNCT00001034Phase 2
• A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) InfectionCompletedNCT00000995Not applicable
• The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDSCompletedNCT00000981Phase 2
• A Study to Evaluate the Effects of Stopping Maintenance Therapy for Cytomegalovirus (CMV) Retinitis After Effective Anti-HIV TherapyCompletedNCT00000905
• A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) DiseaseWithdrawnNCT00000881Phase 1
• A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus DiseaseCompletedNCT00000805Phase 1
• Viral Activation Transfusion Study (VATS)CompletedNCT00000593Not applicable
• Transfusion-Transmitted Cytomegalovirus Prevention in NeonatesCompletedNCT00000584Phase 3

← Cytomegalovirus Infections overview